Discover pivotal Phase 3 trial results for Pfizer's Abrysvo vaccine in adults 18-59 at risk of severe RSV disease. Achieved immunogenicity and safety milestones pave the way for potential regulatory approval, addressing a critical unmet need.
The randomized, double-blind, placebo-controlled MONeT trial evaluated the immunogenicity and safety of Abrysvo in adults 18 years and older at risk of RSV-associated disease. The phase 3 MONeT trial evaluated Abrysvo in adults 18 to 59 years of age at risk of RSV-associated disease.
(CNN) — An RSV vaccine already used for older adults could help protect people as young as 18 who are at increased risk of the disease, drugmaker Pfizer said in
An RSV vaccine already used for older adults could help protect people as young as 18 who are at increased risk of the disease, drugmaker Pfizer said in a news
Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing p